What is Heart Failure and What are the Treatment Options? Complex Questions

Resynchronization and Defibrillation for Heart Failure: A Practical Approach

Volumn , Issue , 2008, Pages 1-38

  Sackner Bernstein, Jonathan ^a  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

ACE inhibitors; Adrenergic antagonists; Heart failure; Prognosis; Ventricular remodeling

Indexed keywords

EID: 84948987986     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470757727.ch1     Document Type: Chapter

References (131)

1. Packer M, Cohn JN, editors. Consensus recommendations for the management of chronic heart failure. Am J Cardiol 1999;83 Suppl 2A:1A-38A.
2. Guideline Committee Members and the Executive Council for the Heart Failure Society of America. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction: pharmacological approaches [published erratum appears in J Card Fail 2000;6:74]. J Card Fail 1999;5:357-82.
3. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Circulation 2001:104:2996-3007.
4. Remme WJ, Swedberg K, Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure [published erratum appears in Eur Heart J 2001;22:2217-8]. Eur Heart J 2001;22:1527-60.
5. Jessup M, Brozena S. Heart failure. N Engl J Med 2003:348:2007-18.
6. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
7. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
8. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions [published erratum appears in N Engl J Med 1992;327:1768]. N Engl J Med 1992;327:685-91.
9. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
10. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al., the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669-77.
11. Torp-Pedersen C, Kober L, Carlsen J. Angio-converting enzyme inhibition after myocardial infarction: the Trandolapril Cardiac Evaluation Study. Am Heart J 1996;132:235-43.
12. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in highrisk patients [published errata appear in N Engl J Med 2000;342:748, 2000;342:1376]. N Engl J Med 2000;342:145-53.
13. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.
14. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
15. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure. Lancet 1999;353:2001-7.
16. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al., for the Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8.
17. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al., and COMET Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003:362:7-13.
18. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al., for the Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8.
19. A randomized trial of propranolol in patients with acute myocardial infarction: II. morbidity results. JAMA 1983;250:2814-9.
20. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al., for the U.S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
21. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al., for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
22. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al., for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction [published erratum appears in N Engl J Med 2003;348:2271]. N Engl J Med 2003:348:1309-21.
23. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al., for the Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996;335:1933-40.
24. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al., for the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 2001;345:1435-43.
25. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, et al., for the MIRACLE Study Group. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002;346:1845-53.
26. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al., for the Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83.
27. Young JB, Abraham WT, Smith AL, Leon AR, Lieberman R, Wilkoff B, Canby RC, et al., for the Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE ICD) Trial Investigators. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA 2003;289:2685-94.
28. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33.
29. Cohn JN. The management of chronic heart failure. N Engl J Med 1996;335:490-8.
30. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease:the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
31. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
32. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
33. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease [published erratum appears in J Card Fail 1998;4:367]. J Card Fail 1997;3:249-54.
34. Bristow MR, Saxon LA, Boehmer J, Krueger S, McGrew F, Botteron G, et al., for the COMPANION Investigators. Cardiac resynchronization therapy (CRT) reduces hospitalizations, and CRT + an implantable defibrillator (CRT-D) reduces mortality in chronic heart failure: preliminary results of the COMPANION trial. Retrieved August 29, 2003, from the World Wide Web: http://www.uchsc.edu/cvi/clb.pdf.
35. Davies M, Hobbs F, Davis R, Kenkre J, Roalfe AK, Hare R, et al. Prevalence of leftventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. Lancet 2001;358:439-44.
36. American Heart Association. Heart Disease and Stroke Statistics-2003 Update. Dallas, TX:American Heart Association; 2002. Retrieved October 6, 2003 from the World Wide Web:http://www.americanheart.org/downloadable/heart/1040391091015HDS_Stats_03.pdf.
37. Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000;343:1603-7.
38. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al., for the Minnesota Colon Cancer Control Study. Reducing mortality from colorectal cancer by screening for fecal ocult blood [published erratum appears in N Engl J Med 1993;329:672]. N Engl J Med 1993;328:1365-71.
39. American Cancer Society. Cancer Facts & Figures 2003. Atlanta, GA: American Cancer Society; 2003. Retrieved October 6, 2003 from the World Wide Web:http://www.cancer.org/docroot/STT/content/STT_1x_Cancer_Facts__Figures_2003.asp.
40. Kannel WB, D'Agostino RB, Silbershatz H, Belanger AJ,Wilson PW, Levy D. Profile for estimating risk of heart failure. Arch Intern Med 1999;159:1197-204.
41. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002;106:3068-72.
42. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80% [published erratum appears in BMJ 2003;327:586]. BMJ 2003;326:1419.
43. Yamamoto K, Burnett JC Jr, Jougasaki M, Nishimura RA, Bailey KR, Saito Y, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996;28:988-94.
44. Dao Q, Krishnaswamy P, Kazanegra R, Harrison A, Amirnovin R, Lenert L, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001;37:379-85.
45. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (NBNP) concentrations. Lancet 2000;355:1126-30.
46. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002;347:1397-402.
47. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with leftventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-90.
48. Rich MW, Beckham V,Wittenberg C, Leven CL, Freedland KE, Carney RM. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995;333:1190-5.
49. Sackner-Bernstein J. Congestive heart failure. In: Curtis JR, Rubenfeld GD, editors. Managing death in the intensive care unit: the transition from cure to comfort. New York: Oxford University Press; 2001. p. 311-7.
50. Mann DL. Mechanisms and models in heart failure: a combinatorial approach. Circulation 1999;100:999-1008.
51. Sackner-Bernstein JD. The myocardial matrix and the development and progression of ventricular remodeling. Curr Cardiol Rep 2000;2:112-9.
52. Colucci WS. The effects of norepinephrine on myocardial biology: implications for the therapy of heart failure. Clin Cardiol 1998;21 Suppl 1:I20-4.
53. St John Sutton M, Pfeffer MA, Plappert T, Rouleau JL, Moye LA, Dagenais GR, et al. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction: the protective effects of captopril. Circulation 1994;89:68-75.
54. Kostuk WJ, Kazamias TM, Gander MP, Simon AL, Ross J Jr. Left ventricular size after acute myocardial infarction: serial changes and their prognostic significance. Circulation 1973;47:1174-9.
55. Migrino RQ, Young JB, Ellis SG, White HD, Lundergan CF, Miller DP, et al., for the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I Angiographic Investigators. End-systolic volume index at 90 to 180 minutes into reperfusion therapy for acute myocardial infarction is a strong predictor of early and late mortality. Circulation 1997;96:116-21.
56. Silver MA. Success with heart failure: help and hope for those with congestive heart failure. Cambridge (MA): Perseus; 2002.
57. Chinese Cardiac Study (CCS-1) Collaborative Group. Oral captopril versus placebo among 14,962 patients with suspected acute myocardial infarction: a multicenter, randomized, double-blind, placebo controlled clinical trial. Chin Med J (Engl) 1997;110:834-8.
58. Olsson G, Tuomilehto J, Berglund G, Elmfeldt D, Warnold I, Barber H, et al. Primary prevention of sudden cardiovascular death in hypertensive patients: mortality results from the MAPHY Study. Am J Hypertens 1991;4:151-8.
59. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314:1547-52.
60. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
61. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al., for the CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-66.
62. Goldstein S. Propranolol therapy in patients with acute myocardial infarction: the Beta-Blocker Heart Attack Trial. Circulation 1983;67 Suppl I:I53-7.
63. Jones CG, Cleland JGF. Meeting report-the LIDO, HOPE, MOXCON and WASH studies. Eur J Heart Fail 1999;1:425-31.
64. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the betablocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659-67.
65. Zebrack JS, Munger MA, MacGregor JF, Stoddard GJ, Gilbert EM. Beta receptor selectivity of carvedilol versus metoprolol succinate: a dose ranging study [abstract]. Circulation 2002;106 Suppl 2:II-612.
66. Kukin ML, Kalman J, Charney RH, Levy DK, Buchholz-Varley C, Ocampo ON, et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 1999;99:2645-51.
67. Sanderson JE, Chan SK, Yip G, Yeung LY, Chan KW, Raymond K, et al. Beta-blockade in heart failure: a comparison of carvedilol with metoprolol. J Am Coll Cardiol 1999;34:1522-8.
68. Di Lenarda A, Sabbadini G, Salvatore L, Sinagra G, Mestroni L, Pinamonti B, et al., and The Heart-Muscle Disease Study Group. J Am Coll Cardiol 1999;33:1926-34.
69. Metra M, Giubbini R, Nodari S, Boldi E, Modena MG, Dei Cas L. Differential effects of β-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 2000;102:546-51.
70. Swedberg K, Bergh CH, Dickstein K, McNay J, Steinberg M, and Moxonidine Investigators. The effects of moxonidine, a novel imidazoline, on plasma norepinephrine in patients with congestive heart failure. J Am Coll Cardiol 2000;35:398-404.
71. Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze GJ. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilolmetoprolol study [published erratum appears in J Hypertens 1996;14:1382]. J Hypertens 1996;14:489-94.
72. Giugliano D, Acampora R, Marfella R, De Rosa N, Ziccardi P, Ragone R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension: a randomized, controlled trial. Ann Intern Med 1997;126:955-9.
73. Garvey WT, Hermayer KL. Clinical implications of the insulin resistance syndrome. Clin Cornerstone 1998;1:13-28.
74. Pontiroli AE, Pacchioni M, Camisasca R, Lattanzio R. Markers of insulin resistance are associated with cardiovascular morbidity and predict overall mortality in longstanding non-insulin-dependent diabetes mellitus. Acta Diabetol 1998;35:52-6.
75. Lempiainen P, Mykkanen L, Pyorala K, Laakso M, Kuusisto J. Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. Circulation 1999;100:123-8.
76. Andersson PE, Lithell H. Metabolic effects of doxazosin and enalapril in hypertriglyceridemic, hypertensive men: relationship to changes in skeletal muscle blood flow. Am J Hypertens 1996;9:323-33.
77. Paolisso G, De Riu S, Marrazzo G, Verza M, Varricchio M, D'Onofrio F. Insulin resistance and hyperinsulinemia in patients with chronic congestive heart failure. Metabolism 1991;40:972-7.
78. Swan JW, Walton C, Godsland IF, Clark AL, Coats AJ, Oliver MF. Insulin resistance in chronic heart failure. Eur Heart J 1994;15:1528-32.
79. Swan JW, Anker SD, Walton C, Godsland IF, Clark AL, Leyva F, et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol 1997;30:527-32.
80. Anker SD, Ponikowski PP, Clark AL, Leyva F, Rauchhaus M, Kemp M, et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J 1999;20:683-93.
81. Francis GS, Goldsmith SR, Levine TB, Olivari MT, Cohn JN. The neurohumoral axis in congestive heart failure. Ann Intern Med 1984;101:370-7.
82. Sackner-Bernstein JD. Use of carvedilol in chronic heart failure: challenges in therapeutic management. Prog Cardiovasc Dis 1998;41 Suppl 1:53-8.
83. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, et al., the ATLAS Study Group. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999;100:2312-8.
84. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al., for the MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807-16.
85. Sackner-Bernstein J, Krum H, Goldsmith RL, Kukin ML, Medina N,Yushak M, et al. Should worsening heart failure early after initiation of beta-blocker therapy for chronic heart failure preclude long-term treatment? [Abstract.] Circulation 1995;92:I-395.
86. Krum H, Roecker EB, Mohacsi P, Rouleau JL, Tendera M, Coats AJ, et al., Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA 2003;289:712-8.
87. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. GISSI-3:effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-22.
88. Køber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, et al., for the Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333:1670-6.
89. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-85.
90. Anderson TJ, Elstein E, Haber H, Charbonneau F. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol 2000;35:60-6.
91. Scholkens BA, Landgraf W. ACE inhibition and atherogenesis. Can J Physiol Pharmacol 2002;80:354-9.
92. Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen PT, Kaartinen M, et al. Expression of antiogensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 2000;101:1372-8.
93. Jackson EK, Garrison JC. Renin and angiotensin. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill; 1996. p. 733-58.
94. The NETWORK Investigators. Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. Eur Heart J 1998;19:481-9.
95. Fogari R, Zoppi A, Corradi L, Lazzari P, Mugellini A, Lusardi P. Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients. Br J Clin Pharmacol 1998;46:467-71.
96. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989;321:868-73.
97. Hunter SJ, Wiggam MI, Ennis CN, Whitehead HM, Sheridan B, Atkinson AB, et al. Comparison of effects of captopril used either alone or in combination with a thiazide diuretic on insulin action in hypertensive Type 2 diabetic patients: a double-blind crossover study. Diabet Med 1999;16:482-7.
98. Weinberger MH. Mechanisms of diuretic effects on carbohydrate tolerance, insulin sensitivity and lipid levels. Eur Heart J 1992;13 Suppl G:5-9.
99. Tomiyama H, Kushiro T, Abeta H, Ishii T, Takahashi A, Furukawa L, et al. Kinins contribute to the improvement of insulin sensitivity during treatment with angiotensin converting enzyme inhibitor. Hypertension 1994;23:450-5.
100. Janssen JJ, Gans RO, van der Meulen J, Pijpers R, ter Wee PM. Comparison between the effects of amlodipine and lisinopril on proteinuria in nondiabetic renal failure: a double-blind, randomized prospective study. Am J Hypertens 1998;11:1074-9.
101. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al., for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
102. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al., for the Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
103. Packer M, Lee WH, Medina N, Yushak M, Kessler PD. Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure. Ann Intern Med 1987;106:346-54.
104. Massie BM, Kramer BL, Topic N. Lack of relationship between the short-term hemodynamic effects of captopril and subsequent clinical responses. Circulation 1984;69:1135-41.
105. Captopril Multicenter Research Group. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol 1983;2:755-63.
106. Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 1986;73:257-67.
107. Packer M, Lee WH, Medina N, Yushak M, Kessler PD, Gottlieb SS. Influence of diabetes mellitus on changes in left ventricular performance and renal function produced by converting enzyme inhibition in patients with severe chronic heart failure. Am J Med 1987;82:1119-26.
108. Dzau VJ, Hollenberg NK. Renal response to captopril in severe heart failure: role of furosemide in natriuresis and reversal of hyponatremia. Ann Intern Med 1984;100:777-82.
109. Packer M, Lee WH, Medina N, Yushak M, Kessler P. Identification of patients with severe heart failure most likely to fail long-term therapy with converting-enzyme inhibitors [abstract]. J Am Coll Cardiol 1986;7:181A.
110. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000;355:637-45.
111. Baruch L, Anand I, Cohen IS, Ziesche S, Judd D, Cohn JN, for the Vasodilator Heart Failure Trial (V-HeFT) Study Group. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Circulation 1999;99:2658-64.
112. Havranek EP, Thomas I, Smith WB, Ponce GA, Bilsker M, Munger MA, et al. Doserelated beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure. J Am Coll Cardiol 1999;33:1174-81.
113. MacFadyen RJ, Lee AF, Morton JJ, Pringle SD, Struthers AD. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 1999;82:57-61.
114. Roig E, Perez-Villa F, Morales M, Jiménez W, Orús J, Heras M, et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 2000;21:53-7.
115. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, et al., the ELITE Study Investigators. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-52.
116. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7.
117. McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure:randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999;100:1056-64.
118. Weber KT, Villarreal D. Aldosterone and antialdosterone therapy in congestive heart failure. Am J Cardiol 1993;71:3A-11A.
119. Lindenfeld J, Robertson AD, Lowes BD, Bristow MR, MOCHA Investigators. Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with betablockers. J Am Coll Cardiol 2001;38:1950-6.
120. Tuzcu EM, Kapadia SR, Tutar E, Ziada KM, Hobbs RE, McCarthy PM, et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults:evidence from intravascular ultrasound. Circulation 2001;103:2705-10.
121. Gattis WA, O'Connor CM, Gheorghiade M. The Initiation Management Predischarge Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) Study:design and implications. Rev Cardiovasc Med 2002;3 Suppl 3:S48-54.
122. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report [published erratum appears in JAMA 2003;290:197]. JAMA 2003;289:2560-72.
123. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies [published erratum appears in Lancet 2003;361:1060]. Lancet 2002;360:1903-13.
124. Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension 2001;38:E28-32.
125. National Cholesterol Education Program. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. September 2002. Retrieved August 29, 2003, from the World Wide Web: http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3_rpt.htm.
126. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16.
127. Cleland JG. Is aspirin "the weakest link" in cardiovascular prophylaxis? The surprising lack of evidence supporting the use of aspirin for cardiovascular disease. Prog Cardiovasc Dis 2002;44:275-92.
128. Adler AI, Stratton IM, Neil HA,Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321:412-9.
129. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2000. Atlanta (GA): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2002. Retrieved August 29, 2003, from the World Wide Web:http://www.diabetes.org/main/info/facts/facts_natl.jsp.
130. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
131. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo- controlled trial. Lancet 2002;360:7-22.